🔎 Trials Near Me

Home › Neoplasms by Histologic Type

Neoplasms by Histologic Type clinical trials recruiting in the U.S.

12 studies for Neoplasms by Histologic Type are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Sep 28, 2026 · NCT07416188

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07075185

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Recruiting
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT05297734

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 2, 2024 · NCT06271252

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.